Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma

NCT01666600 is registered in ClinicalTrials.gov with Prof. Dr. Wolfgang Wick as lead sponsor.

NCT NCT01666600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01666600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma
Lead sponsor
Prof. Dr. Wolfgang Wick
Phase
Phase 1/2
Overall status
Terminated
Start date
August 31, 2012
Completion date
September 30, 2017
Enrollment
63 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme